“Metastatic HER2-Positive Breast Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metastatic HER2-Positive Breast Cancer Market.
The Metastatic HER2-Positive Breast Cancer Pipeline report embraces in-depth commercial, regulatory, and Metastatic HER2-Positive Breast Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Metastatic HER2-Positive Breast Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Metastatic HER2-Positive Breast Cancer Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Metastatic HER2-Positive Breast Cancer treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Metastatic HER2-Positive Breast Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Metastatic HER2-Positive Breast Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Metastatic HER2-Positive Breast Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic HER2-positive breast Cancer therapeutic market.
Metastatic HER2-Positive Breast Cancer Therapeutics Landscape
The market comprises a variety of options for the treatment of HER-2 Positive Metastatic Breast Cancer. Treatment, which is mainly categorized into pharmacological and non-pharmacological therapies. Systemic therapies are generally prescribed by a medical oncologist. Common ways to give systemic therapies include an intravenous tube or can be given orally.
The systemic therapies used for metastatic breast cancer include Targeted Therapy and Hormonal therapy(Endocrine therapy). Although the first-line treatment of metastatic breast cancer is mainly dependent on the receptor status, both estrogen and progesterone receptor status and HER2 receptor status should be tested. If the tumor represents both HER2-positive and estrogen receptor-positive then initial treatment may include hormonal therapy or a HER2-targeted therapy or both. In hormonal therapy, Tamoxifen (AstraZeneca Pharmaceuticals) is a drug that blocks estrogen from binding
On the other hand, hormonal therapy market also includes Aromatase Inhibitors that reduce the production of estrogen by inhibiting the aromatase enzyme activity in peripheral tissues and within the tumor microenvironment. The market landscape of aromatase inhibitors mainly depends on three agents, Exemestane (Pharmacia & Upjohn Company), Anastrozole (AstraZeneca), and Letrozole (Novartis Pharmaceuticals).
Thus far, HER2-targeted agents Herceptin (Trastuzumab), Tykerb (Lapatinib), Perjeta (Pertuzumab), Nerlynx (Neratinib), Enhertu (Daiichi Sankyo) and Kadcyla (ado-trastuzumab emtansine) have been approved for the treatment of HER2-positive metastatic breast cancer patients. Much of their current use is driven by the design of the studies that led to their regulatory approval, but much remains unknown about their optimal use, alone or in combination.
Metastatic HER2-Positive Breast Cancer Companies Actively Working in the Therapeutic Market Include:
-
MacroGenics
-
Roche
-
Genentech
-
Pfizer
-
Merck Sharp & Dohme
-
Eli Lilly and Company
And Many Others
Emerging and Marketed Metastatic HER2-Positive Breast Cancer Drugs Covered in the Report Include:
-
Margetuximab (MacroGenics)
-
Tecentriq/ Atezolizumab (Roche/ Genentech),
-
Ibrance/ Palbociclib (Pfizer)
-
Keytruda/ Pembrolizumab (Merck Sharp and Dohme)
-
Abemaciclib/ LY2835219 (Eli Lilly and Company)
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Metastatic HER2-Positive Breast Cancer Companies Working in the Market @
https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-pipeline-insight
Analysis of Emerging Metastatic HER2-Positive Breast Cancer Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Learn How the Metastatic HER2-Positive Breast Cancer Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Metastatic HER2-Positive Breast Cancer Treatment Patterns
4. Metastatic HER2-Positive Breast Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Metastatic HER2-Positive Breast Cancer Late Stage Products (Phase-III)
7. Metastatic HER2-Positive Breast Cancer Mid-Stage Products (Phase-II)
8. Metastatic HER2-Positive Breast Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic HER2-Positive Breast Cancer Discontinued Products
13. Metastatic HER2-Positive Breast Cancer Product Profiles
14. Major Metastatic HER2-Positive Breast Cancer Companies in the Market
15. Key Products in the Metastatic HER2-Positive Breast Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Metastatic HER2-Positive Breast Cancer Unmet Needs
18. Metastatic HER2-Positive Breast Cancer Future Perspectives
19. Metastatic HER2-Positive Breast Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Esophageal Squamous Carcinoma Market
“Esophageal Squamous Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Esophageal Squamous Carcinoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Esophageal Squamous Carcinoma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices